Whether you need routine screening, are concerned about breast pain, or face a complicated cancer diagnosis, we stand with you every step of the way.
use is more start-and-stop than most people assumed." To better understand what influences treatment patterns, the researchers used Cox proportional hazards models and examined sociodemographic, clinical and provider-level factors
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
I posted this video 4 years ago
9-11 If a GLP-1 RA is determined to be the best option for the patient, pharmacists and providers should consider the following recommendations: Follow dosing recommendations as directed by the manufacturer
